FRA:MRK - Merck Group Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
€85.36 +1.66 (+1.98 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close€85.36
Today's Range€83.34 - €85.36
52-Week Range€76.60 - €115.00
Volume757,883 shs
Average VolumeN/A
Market Capitalization$10.07 billion
P/E RatioN/A
Dividend Yield1.59%
BetaN/A

About Merck Group (FRA:MRK)

Merck Group logoMERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. It also provides over-the counter and food supplement products under the Neurobion, Bion3, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Vivera/Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brands. In addition, the company offers life science products and services for use in the discovery, development, and manufacture of biotechnological drugs, as well as in research and application laboratories; and specialty chemicals and functional materials for applications consumer electronics, lighting, coatings, printing technology, paints, plastics, and cosmetics. It has strategic alliances with Pfizer Inc. and Baylor College of Medicine; an agreement with Bristol-Myers Squibb Company for the co-commercialization of Glucophage, an antidiabetic agent in China; a strategic collaboration and license agreement with Intrexon Corporation to develop and commercialize chimeric antigen receptor T-cell cancer therapies; and collaborations with F-star Delta Ltd. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolFRA:MRK
CUSIPN/A
Phone+49-6151-720

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares129,240,000

Merck Group (FRA:MRK) Frequently Asked Questions

What is Merck Group's stock symbol?

Merck Group trades on the FRA under the ticker symbol "MRK."

What price target have analysts set for MRK?

22 brokerages have issued twelve-month target prices for Merck Group's shares. Their predictions range from €84.00 to €125.00. On average, they anticipate Merck Group's share price to reach €100.62 in the next year. View Analyst Ratings for Merck Group.

Who are some of Merck Group's key competitors?

Who are Merck Group's key executives?

Merck Group's management team includes the folowing people:
  • Dr. Stefan Oschmann, Chairman of Exec. Board & Chief Exec. Officer (Age 61)
  • Dr. Marcus Kuhnert, Chief Financial Officer & Member of Exec. Board (Age 50)
  • Dr. Walter Galinat, Member of Exec. Board (Age 62)
  • Dr. Kai Beckmann, Member of the Exec. Board & CEO of Performance Materials (Age 53)
  • Dr. Udit Batra, Member of Exec. Board & Chief Exec. Officer of Life Sciences (Age 47)

Has Merck Group been receiving favorable news coverage?

News articles about MRK stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Merck Group earned a media sentiment score of 0.18 on Accern's scale. They also assigned media stories about the healthcare company an impact score of 47.20 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

What is Merck Group's stock price today?

One share of MRK stock can currently be purchased for approximately €85.36.

How big of a company is Merck Group?

Merck Group has a market capitalization of $10.07 billion.

How can I contact Merck Group?

Merck Group's mailing address is Frankfurter Strasse 250, DARMSTADT, 64293, Germany. The healthcare company can be reached via phone at +49-6151-720.


MarketBeat Community Rating for Merck Group (MRK)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  546 (Vote Outperform)
Underperform Votes:  700 (Vote Underperform)
Total Votes:  1,246
MarketBeat's community ratings are surveys of what our community members think about Merck Group and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Merck Group (FRA:MRK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
22 Wall Street analysts have issued ratings and price targets for Merck Group in the last 12 months. Their average twelve-month price target is €100.62The high price target for MRK is €125.00 and the low price target for MRK is €84.00. There are currently 11 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.522.52
Ratings Breakdown: 0 Sell Rating(s)
11 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: €100.62€100.62€108.25€109.50

Merck Group (FRA:MRK) Consensus Price Target History

Price Target History for Merck Group (FRA:MRK)

Merck Group (FRA:MRK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
4/4/2018Sanford C. BernsteinSet Price TargetBuy€105.00View Rating Details
4/4/2018UBSSet Price TargetBuy€115.00View Rating Details
4/3/2018JPMorgan Chase & Co.Set Price TargetNeutral€90.00View Rating Details
3/27/2018CommerzbankSet Price TargetNeutral€90.00View Rating Details
3/21/2018Goldman Sachs GroupSet Price TargetNeutral€92.00View Rating Details
3/21/2018Deutsche BankSet Price TargetNeutral€85.00View Rating Details
3/19/2018Berenberg BankSet Price TargetBuy€106.00View Rating Details
3/12/2018Kepler Capital MarketsSet Price TargetBuy€106.00View Rating Details
3/12/2018DZ BankReiterated RatingBuyView Rating Details
3/12/2018Nord/LBSet Price TargetNeutral€84.00View Rating Details
3/9/2018CfraSet Price TargetNeutral€85.00View Rating Details
3/9/2018Credit Suisse GroupSet Price TargetNeutral€85.00View Rating Details
3/9/2018Societe GeneraleSet Price TargetNeutral€88.00View Rating Details
3/8/2018Independent ResearchSet Price TargetNeutral€88.00View Rating Details
3/7/2018Warburg ResearchSet Price TargetBuy€115.00View Rating Details
12/6/2017Bank of AmericaSet Price TargetNeutral€95.00View Rating Details
12/1/2017Morgan StanleySet Price TargetNeutral€98.00View Rating Details
11/10/2017Oddo BhfSet Price TargetBuy€125.00View Rating Details
11/9/2017S&P GlobalSet Price TargetBuy€110.00View Rating Details
11/3/2017equinetSet Price TargetBuy€112.00View Rating Details
10/2/2017CitigroupSet Price TargetBuy€123.00View Rating Details
9/6/2017BNP ParibasSet Price TargetBuy€116.00View Rating Details
11/15/2016Bankhaus LampeSet Price TargetBuy€112.00View Rating Details
8/5/2016Baader BankSet Price TargetNeutral€97.00View Rating Details
(Data available from 5/25/2016 forward)

Earnings

Dividends

Merck Group (FRA:MRK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Merck Group (FRA MRK) Insider Trading and Institutional Ownership History

Insider Trading History for Merck Group (FRA:MRK)

Merck Group (FRA MRK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Merck Group (FRA MRK) News Headlines

Source:
DateHeadline
Merck Group (MRK) Receives Consensus Rating of "Hold" from AnalystsMerck Group (MRK) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - May 24 at 12:33 PM
Merck’s experimental and unlicensed Ebola vaccine is being used in latest outbreakMerck’s experimental and unlicensed Ebola vaccine is being used in latest outbreak
www.marketwatch.com - May 22 at 4:00 PM
9 Companies Bracing for Big ASCO Reactions9 Companies Bracing for Big ASCO Reactions
www.msn.com - May 19 at 9:55 AM
Merck KGaA, Darmstadt, Germany Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology PipelineMerck KGaA, Darmstadt, Germany Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline
finance.yahoo.com - May 17 at 10:18 AM
Top Analyst Reports for Home Depot, Merck & RaytheonTop Analyst Reports for Home Depot, Merck & Raytheon
www.zacks.com - May 16 at 10:19 AM
Biotechs Emerge Unscathed And Ready To Go!Biotechs Emerge Unscathed And Ready To Go!
www.msn.com - May 15 at 10:40 AM
Merck KGaA Q1 earnings down on liquid crystals, currenciesMerck KGaA Q1 earnings down on liquid crystals, currencies
finance.yahoo.com - May 15 at 10:40 AM
[$$] Merck KGaAs Sales Fall[$$] Merck KGaA's Sales Fall
finance.yahoo.com - May 15 at 10:40 AM
Merck KGaA Sees Profit Falling on Liquid Crystals StruggleMerck KGaA Sees Profit Falling on Liquid Crystals Struggle
finance.yahoo.com - May 15 at 10:40 AM
Has Merck (MRK) Outpaced Other Medical Stocks This Year?Has Merck (MRK) Outpaced Other Medical Stocks This Year?
www.zacks.com - May 8 at 4:00 PM
Mercks BACE-Inhibitor Alzheimers WipeoutMerck's BACE-Inhibitor Alzheimer's Wipeout
seekingalpha.com - May 6 at 10:09 AM
Lessons to Learn From Aprils Biotech BlowupsLessons to Learn From April's Biotech Blowups
finance.yahoo.com - April 25 at 4:10 PM
Germanys Merck seeks partners for cancer and immune system drugsGermany's Merck seeks partners for cancer and immune system drugs
finance.yahoo.com - April 20 at 4:04 PM
FOCUS-Germanys Merck seeks partners for cancer and immune system drugsFOCUS-Germany's Merck seeks partners for cancer and immune system drugs
finance.yahoo.com - April 20 at 10:17 AM
[$$] P&G Needs a Workout, Not Vitamins[$$] P&G Needs a Workout, Not Vitamins
finance.yahoo.com - April 19 at 4:11 PM
P&G Exec: The Entire Board Was Supportive of Our $4.2 Billion DealP&G Exec: The Entire Board Was Supportive of Our $4.2 Billion Deal
finance.yahoo.com - April 19 at 4:11 PM
DZ Bank Reaffirms "Sell" Rating for Merck Group (MRK)DZ Bank Reaffirms "Sell" Rating for Merck Group (MRK)
www.americanbankingnews.com - April 17 at 5:54 PM
Why Bristol-Myers Squibb is making a big bet its approach to treating lung cancer is the right one (MRK, BMY)Why Bristol-Myers Squibb is making a big bet its approach to treating lung cancer is the right one (MRK, BMY)
www.msn.com - April 17 at 10:23 AM
Bristol-Myers Opdivo/Yervoy combo beats chemo in first-line lung cancer; shares down 5% on Merck Keytruda dataBristol-Myers' Opdivo/Yervoy combo beats chemo in first-line lung cancer; shares down 5% on Merck Keytruda data
seekingalpha.com - April 16 at 3:59 PM
With Lackluster Growth, Mercks Shareholders Need To Act NowWith Lackluster Growth, Merck's Shareholders Need To Act Now
seekingalpha.com - April 16 at 3:59 PM
Berenberg Bank Analysts Give Merck Group (MRK) a €110.00 Price TargetBerenberg Bank Analysts Give Merck Group (MRK) a €110.00 Price Target
www.americanbankingnews.com - April 15 at 11:10 PM
Deutsche Bank Analysts Give Merck Group (MRK) a €106.00 Price TargetDeutsche Bank Analysts Give Merck Group (MRK) a €106.00 Price Target
www.americanbankingnews.com - April 15 at 10:34 PM
JPMorgan Chase Analysts Give Merck Group (MRK) a €100.00 Price TargetJPMorgan Chase Analysts Give Merck Group (MRK) a €100.00 Price Target
www.americanbankingnews.com - April 15 at 10:34 PM
Credit Suisse Group Reiterates €106.00 Price Target for Merck Group (MRK)Credit Suisse Group Reiterates €106.00 Price Target for Merck Group (MRK)
www.americanbankingnews.com - April 15 at 10:00 PM
Kepler Capital Markets Analysts Give Merck Group (MRK) a €119.00 Price TargetKepler Capital Markets Analysts Give Merck Group (MRK) a €119.00 Price Target
www.americanbankingnews.com - April 15 at 8:37 AM
Venture Capital Deals Of The Week: Tencent Led $3B InvestmentVenture Capital Deals Of The Week: Tencent Led $3B Investment
seekingalpha.com - April 14 at 3:40 PM
Merck Group (MRK) Given a €110.00 Price Target by Berenberg Bank AnalystsMerck Group (MRK) Given a €110.00 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - April 13 at 9:58 PM
Goldman Sachs Reiterates €110.00 Price Target for Merck Group (MRK)Goldman Sachs Reiterates €110.00 Price Target for Merck Group (MRK)
www.americanbankingnews.com - April 13 at 12:59 PM
Merck Group (MRK) Given a €106.00 Price Target at Deutsche BankMerck Group (MRK) Given a €106.00 Price Target at Deutsche Bank
www.americanbankingnews.com - April 13 at 10:15 AM
Merck Group (MRK) Given a €109.00 Price Target at CommerzbankMerck Group (MRK) Given a €109.00 Price Target at Commerzbank
www.americanbankingnews.com - April 12 at 4:31 PM
 Analysts Give Merck Group (MRK) a €94.00 Price Target Analysts Give Merck Group (MRK) a €94.00 Price Target
www.americanbankingnews.com - April 12 at 2:53 PM
US STOCKS-Wall St edges higher as techs gain, trade war worries ebbUS STOCKS-Wall St edges higher as techs gain, trade war worries ebb
www.nasdaq.com - April 10 at 10:26 AM
Merck Tackles Front-Line Lung Cancer In Latest Trial WinMerck Tackles Front-Line Lung Cancer In Latest Trial Win
seekingalpha.com - April 10 at 10:26 AM
Pre-Open Movers 04/09: (AVXS) (RGNX) (VSTM) Higher; (MNLO) (ACAD) (MTG) Lower (more...)Pre-Open Movers 04/09: (AVXS) (RGNX) (VSTM) Higher; (MNLO) (ACAD) (MTG) Lower (more...)
www.streetinsider.com - April 9 at 3:59 PM
US STOCKS-Wall St higher as tech stocks gain, trade war worries ebbUS STOCKS-Wall St higher as tech stocks gain, trade war worries ebb
www.nasdaq.com - April 9 at 3:59 PM
Provectus Biopharmaceuticals Is An Opportunity With Great Risk And Great Potential RewardProvectus Biopharmaceuticals Is An Opportunity With Great Risk And Great Potential Reward
seekingalpha.com - April 9 at 3:59 PM
Merck Group (MRK) Given a €103.00 Price Target by Morgan Stanley AnalystsMerck Group (MRK) Given a €103.00 Price Target by Morgan Stanley Analysts
www.americanbankingnews.com - April 8 at 9:42 PM
Merck Group (MRK) Receives New Coverage from Analysts at UBSMerck Group (MRK) Receives New Coverage from Analysts at UBS
www.americanbankingnews.com - April 8 at 6:28 PM
Merck Group (MRK) PT Set at €123.00 by CitigroupMerck Group (MRK) PT Set at €123.00 by Citigroup
www.americanbankingnews.com - April 8 at 4:53 PM
Merck Group (MRK) PT Set at €115.00 by Warburg ResearchMerck Group (MRK) PT Set at €115.00 by Warburg Research
www.americanbankingnews.com - April 8 at 4:51 PM
UBS Reiterates "€120.00" Price Target for Merck Group (MRK)UBS Reiterates "€120.00" Price Target for Merck Group (MRK)
www.americanbankingnews.com - April 8 at 4:51 PM
Merck Group (MRK) PT Set at €116.00 by Berenberg BankMerck Group (MRK) PT Set at €116.00 by Berenberg Bank
www.americanbankingnews.com - April 8 at 4:17 PM
Merck KGaA (MRK) Given a €103.00 Price Target at CommerzbankMerck KGaA (MRK) Given a €103.00 Price Target at Commerzbank
www.americanbankingnews.com - April 4 at 10:25 PM
Merck KGaA (MRK) PT Set at €115.00 by UBSMerck KGaA (MRK) PT Set at €115.00 by UBS
www.americanbankingnews.com - April 4 at 1:03 PM
Sanford C. Bernstein Analysts Give Merck KGaA (MRK) a €105.00 Price TargetSanford C. Bernstein Analysts Give Merck KGaA (MRK) a €105.00 Price Target
www.americanbankingnews.com - April 4 at 11:57 AM
Merck KGaA (MRK) Receives Average Rating of "Hold" from BrokeragesMerck KGaA (MRK) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 4 at 9:58 AM
Merck KGaA (MRK) Given a €90.00 Price Target by JPMorgan Chase AnalystsMerck KGaA (MRK) Given a €90.00 Price Target by JPMorgan Chase Analysts
www.americanbankingnews.com - April 3 at 9:17 AM
Merck KGaA (MRK) PT Set at €100.00 by JPMorgan ChaseMerck KGaA (MRK) PT Set at €100.00 by JPMorgan Chase
www.americanbankingnews.com - April 2 at 4:46 PM
Merck KGaA (MRK) Given a €116.00 Price Target at Berenberg BankMerck KGaA (MRK) Given a €116.00 Price Target at Berenberg Bank
www.americanbankingnews.com - March 31 at 9:24 PM
Commerzbank Analysts Give Merck KGaA (MRK) a €103.00 Price TargetCommerzbank Analysts Give Merck KGaA (MRK) a €103.00 Price Target
www.americanbankingnews.com - March 31 at 9:24 PM

SEC Filings

Merck Group (FRA:MRK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Merck Group (FRA MRK) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.